Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Sees Significant Drop in Short Interest

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 4,248,996 shares, a drop of 19.8% from the December 15th total of 5,300,558 shares. Based on an average daily trading volume, of 875,914 shares, the short-interest ratio is presently 4.9 days. Currently, 4.0% of the company’s shares are sold short. Currently, 4.0% of the company’s shares are sold short. Based on an average daily trading volume, of 875,914 shares, the short-interest ratio is presently 4.9 days.

Insider Transactions at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 10,787 shares of the company’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total value of $188,017.41. Following the transaction, the insider directly owned 52,391 shares in the company, valued at $913,175.13. The trade was a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.96% of the company’s stock.

Institutional Trading of Zai Lab

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZLAB has been the subject of several analyst reports. UBS Group began coverage on Zai Lab in a research note on Wednesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.30.

Zai Lab Stock Down 1.3%

Shares of Zai Lab stock opened at $18.58 on Tuesday. Zai Lab has a fifty-two week low of $16.82 and a fifty-two week high of $44.34. The business has a 50-day moving average price of $19.01 and a 200 day moving average price of $27.77. The firm has a market cap of $2.08 billion, a P/E ratio of -9.53 and a beta of 0.83.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Zai Lab had a negative net margin of 46.83% and a negative return on equity of 25.83%. The company had revenue of $116.10 million during the quarter, compared to the consensus estimate of $150.24 million. As a group, equities research analysts anticipate that Zai Lab will post -2.58 earnings per share for the current year.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.